Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) [homepage on the Internet]Global Strategy for the Diagnosis, Management and Prevention of COPD Available from: http://www.goldcopd.org/Accessed January 25, 2016
   Google Scholar
• World Health Organization (WHO) [webpage on the Internet]Chronic Respiratory Diseases Available from: http://www.who.int/respiratory/copd/en/Accessed November 23, 2015
   Google Scholar
• DonaldsonGCSeemungalTARBhowmikAWedzichaJARelationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax2002571084785212324669
   PubMed Web of Science ®Google Scholar
• DonaldsonGCCOPD exacerbations – 1: epidemiologyThorax200661216416816443707
   PubMed Web of Science ®Google Scholar
• WedzichaJABrillSEAllinsonJPDonaldsonGCMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseaseBMC Med20131118123945277
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence [webpage on the Internet]NICE Guidelines [CG101]: Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (Partial Update)LondonNational Institute for Health and Care Excellence2010 Available from: http://www.nice.org.uk/guidance/CG101Accessed November 3, 2015
   Google Scholar
• MiravitllesMVogelmeierCRocheNA review of national guidelines for management of COPD in EuropeEur Respir J201647262563726797035
   PubMed Web of Science ®Google Scholar
• WilkieMFinchSSchembriSInhaled corticosteroids for chronic obstructive pulmonary disease – the shifting treatment paradigmCOPD J Chronic Obstr Pulm Dis2015125582590
   PubMed Web of Science ®Google Scholar
• VestboJHurdSSAgustíAGGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summaryAm J Respir Crit Care Med2013187434736522878278
   PubMed Web of Science ®Google Scholar
• CazzolaMPageCLong-acting bronchodilators in COPD: where are we now and where are we going?Breathe201410110120
   Google Scholar
• NanniniLCatesCJLassersonTJPoolePCombined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20043CD00379415266502
   PubMed Web of Science ®Google Scholar
• HalpinDMGGrayJEdwardsSJMoraisJSinghDBudesonide/formoterol vs salmeterol/fluticasone in COPD: a systematic review and adjusted indirect comparison of pneumonia in randomised controlled trials: budesonide/formoterol vs salmeterol/fluticasone in COPD: pneumoniaInt J Clin Pract201165776477421676119
   PubMed Web of Science ®Google Scholar
• LarssonKJansonCLisspersKCombination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS studyJ Intern Med2013273658459423495860
   PubMed Web of Science ®Google Scholar
• LatorreMNovelliFVagagginiBDifferences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICSPulm Pharmacol Ther201530445025445928
   PubMed Web of Science ®Google Scholar
• AIFAGuidelineAIFA Guideline for the Classification and Conduction of the Observational Studies on Medicines2008 Available from: https://www.agenziafarmaco.gov.it/ricclin/sites/default/files/files_wysiwyg/files/CIRCULARS/Circular%2031st%20May%202010.pdfAccessed September 15, 2016
   Google Scholar
• GonnellaJSLouisDZGozumMVCallahanCABarnesCADisease Staging Clinical and Coded Criteria. Version 5.26Ann Arbor, MIThomson Medstat2010
   Google Scholar
• Budesonide/Formoterol [prescribing information]European Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003951/human_med_001807.jsp&mid=WC0b01ac058001d124Accessed January 22, 2016
   Google Scholar
• Fluticasone/Salmeterol [prescribing information]European Medicines Agency Available from: http://www.ema.europa.eu/docs/it_IT/document_library/Referrals_document/Seretide_Diskus_6_13/WC500013534.pdfAccessed January 22, 2016
   Google Scholar
• BlaisLForgetARamachandranSRelative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherenceClin Ther20103271320132820678680
   PubMed Web of Science ®Google Scholar
• KernDMDavisJWilliamsSAComparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database studyRespir Res2015165225899176
   PubMed Web of Science ®Google Scholar
• BurgeSWedzichaJACOPD exacerbations: definitions and classificationsEur Respir J20032146S53S
   Web of Science ®Google Scholar
• GibsonGJLoddenkemperRLundbackBSibilleYRespiratory health and disease in Europe: the new European Lung White BookEur Respir J201342355956324000245
   PubMed Web of Science ®Google Scholar
• AballéaSCureSVogelmeierCWirénAA retrospective database study comparing treatment outcomes and cost associated with choice of fixed-dose inhaled corticosteroid/long-acting β2-agonists for asthma maintenance treatment in Germany: comparison of fixed-dose combinations for asthmaInt J Clin Pract2008621870187918803555
   PubMed Web of Science ®Google Scholar
• RoggeriAMichelettoCRoggeriDPOutcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS studyInt J Chron Obstruct Pulmon Dis2014956957624940053
   PubMed Web of Science ®Google Scholar
• RobertsMMapelDPetersenHBlanchetteCRamachandranSComparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD managementJ Med Econ201114676977621942463
   PubMedGoogle Scholar
• PunekarYSLandisSHWurstKLeHCharacteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary careRespir Res20151614126572740
   PubMed Web of Science ®Google Scholar
• HerseFKiljanderTLehtimäkiLAnnual costs of chronic obstructive pulmonary disease in Finland during 1996–2006 and a prediction model for 2007–2030Npj Prim Care Respir Med2015251501525811648
   PubMed Web of Science ®Google Scholar
• PunekarYSShuklaAMüllerovaHCOPD management costs according to the frequency of COPD exacerbations in UK primary careInt J Chron Obstruct Pulmon Dis20149657324426781
   PubMed Web of Science ®Google Scholar